Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Crinetics PharmaceuticalsFRA:6Z4 -1.23%50 Days Inventory is 1,154.34 as of Mar. 2026, which is 68% above its 10-year median of 685.90. GuruFocus rates FRA:6Z4 with a GF Score™ of 50/100 and a GF Value™ of €626.58 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 638 Biotechnology companies, Crinetics Pharmaceuticals ranks worse than 96.87% on this metric.
If a company builds up inventory, it may mean it is having difficulties selling its goods.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Crinetics Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.08.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Crinetics Pharmaceuticals's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 0.24.
Crinetics Pharmaceuticals (FRA:6Z4) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Crinetics Pharmaceuticals's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Crinetics Pharmaceuticals's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Crinetics Pharmaceuticals Days Inventory Related Terms
Crinetics Pharmaceuticals Days Inventory Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6Z4 vs CPRX, NAMS, RCUS: Days Inventory Comparison
For the Biotechnology subindustry, Crinetics Pharmaceuticals's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crinetics Pharmaceuticals Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crinetics Pharmaceuticals's Days Inventory distribution charts can be found below:
* The bar in red indicates where Crinetics Pharmaceuticals's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crinetics Pharmaceuticals (FRA:6Z4) has a Days Inventory of 1,154.34 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Crinetics Pharmaceuticals and its competitors. This is 68% above median its historical median of 685.90. Over the past decade, Crinetics Pharmaceuticals' Days Inventory has ranged from 685.90 to 4,640.98. According to the industry distribution chart, Crinetics Pharmaceuticals ranks #618 out of 638 companies in the Biotechnology industry, placing it in the top 96.9%.
Is Crinetics Pharmaceuticals' Days Inventory too high?
Crinetics Pharmaceuticals' current Days Inventory of 1,154.34 is 68% above median its 10-year median of 685.90. Over the past 10 years, this metric has ranged from a low of 685.90 to a high of 4,640.98. The Biotechnology industry median Days Inventory is 183.20. Crinetics Pharmaceuticals' value of 1,154.34 is 530.1% above this industry median. Based on the distribution chart, Crinetics Pharmaceuticals ranks #618 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Crinetics Pharmaceuticals has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Crinetics Pharmaceuticals' Days Inventory compare to CPRX and NAMS?
According to the Biotechnology industry distribution chart, Crinetics Pharmaceuticals ranks #618 out of 638 companies for Days Inventory. This places Crinetics Pharmaceuticals in the lower half of its industry. The industry median Days Inventory is 183.20. Crinetics Pharmaceuticals' value of 1,154.34 is 530.1% above this benchmark. Historically, Crinetics Pharmaceuticals' own Days Inventory has ranged from 685.90 to 4,640.98 over the past decade. While the company's 10-year median is 685.90 vs. the industry median of 183.20, Crinetics Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 183.20, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crinetics Pharmaceuticals's current Days Inventory of 1,154.34 is 530.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Crinetics Pharmaceuticals and its competitors. For the Biotechnology industry, the median Days Inventory is 183.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crinetics Pharmaceuticals's current Days Inventory is 1,154.34, which is 68% above median its own 10-year median of 685.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crinetics Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals (FRA:6Z4) is currently considered Possible Value Trap. The stock's GF Value™ is €626.58, compared to a current price of €70.90 — trading 88.7% below its estimated fair value. The current Days Inventory is 1,154.34, which is 68% above median its 10-year median of 685.90 and 530.1% above the Biotechnology industry median of 183.20. Crinetics Pharmaceuticals' overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Crinetics Pharmaceuticals (FRA:6Z4), the current Days Inventory is 1,154.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Crinetics Pharmaceuticals (FRA:6Z4) Overvalued in 2026?
Based on GuruFocus' analysis, Crinetics Pharmaceuticals stock appears to be undervalued.
The current stock price of €70.90 is trading 88.7% below its estimated GF Value™ of €626.58.
GuruFocus considers Crinetics Pharmaceuticals to be Possible Value Trap.
Key valuation signals for FRA:6Z4:
Days Inventory: 1,154.34 (68% above median its 10-year median of 685.90)
GF Value™: €626.58 vs. price of €70.90 (88.7% below fair value)
Industry Position: 530.1% above the Biotechnology median (#618 of 638)
No single metric tells the full story. See the FRA:6Z4 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
50GF Score
Get the complete analysis for FRA:6Z4
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6Z4 has been successfully added to your 
